HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The genetics of cystic fibrosis: a paradigm for uncovering new drug targets.

Abstract
A broad-based approach will be required for the development of new therapies for cystic fibrosis lung disease. Recently, rapid progress has been made in identifying and testing a number of gene transfer vectors, including adenoviral vectors and liposomes. Major problems, however, have been identified with respect to the efficiency of these systems. Preliminary studies suggest that small molecules (e.g. amelioride and UTP) may normalize the clearance of secretions from the cystic fibrosis lung. The concept of recombinant protein based therapy for cystic fibrosis has now been realized with the successful application of DNase in clinical trials.
AuthorsR C Boucher
JournalCurrent opinion in biotechnology (Curr Opin Biotechnol) Vol. 5 Issue 6 Pg. 639-42 (Dec 1994) ISSN: 0958-1669 [Print] England
PMID7531034 (Publication Type: Journal Article, Review)
Chemical References
  • CFTR protein, human
  • Chloride Channels
  • Liposomes
  • Membrane Proteins
  • Sodium Channels
  • Cystic Fibrosis Transmembrane Conductance Regulator
Topics
  • Animals
  • Chloride Channels (drug effects)
  • Cystic Fibrosis (complications, genetics, therapy)
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • Genetic Therapy
  • Genetic Vectors
  • Humans
  • Liposomes
  • Membrane Proteins (genetics)
  • Sodium Channels (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: